Determinants of switch to paediatric second-line antiretroviral therapy after first-line failure in Cameroon

被引:2
|
作者
Njom-Nlend, Anne-Esther [1 ,2 ]
Efouba, Nadege [2 ]
Brunelle Sandie, Arsene [3 ]
Fokam, Joseph [4 ,5 ,6 ,7 ]
机构
[1] Natl Social Insurance Fund Hosp, Essos Hosp Ctr, Yaounde, Cameroon
[2] Univ Douala, Higher Inst Med Technol, Yaounde, Cameroon
[3] Pan African Univ, Nairobi, Kenya
[4] Chantal BIYA Int Reference Ctr Res HIV AIDS Preve, Yaounde, Cameroon
[5] Univ Buea, Fac Hlth Sci, Buea, Cameroon
[6] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon
[7] Minist Publ Hlth, Natl HIV Drug Resistance Working Grp, Yaounde, Cameroon
关键词
predictors; switch to second‐ line; antiretroviral therapy; HIV; children; HIV-INFECTED CHILDREN; VIROLOGICAL FAILURE; PREDICTORS; ADOLESCENTS; MORTALITY; HIV/AIDS; OUTCOMES; AFRICA; ART;
D O I
10.1111/tmi.13595
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective With scale-up of antiretroviral therapy (ART) children, treatment failure and switch to subsequent ART regimens are common. Our objectives were to evaluate switching practices and identify factors associated among children and adolescents failing their first-line ART. Methods A facility-based survey study was conducted in a cohort of children living with HIV experiencing virological failure (VF) at the Essos Hospital Centre of Yaounde, Cameroon. Data were collected using a standard questionnaire, and key variables were as follows: (a) VF defined as viral load (VL) > 1000 copies/ml, (b) rate of switch to second-line and (c) reason(s) for switching ART. Odds ratio (OR) with 95% confidence interval (CI) was used to assess the association between study variables, and P A total of 106 children experiencing VF were enrolled: median age was 8 [interquartile range (IQR): 3-15] years; 60.38% were boys and 39.62% were orphans of one/both parents. A proportion of 69% were at the WHO clinical stage III/IV, and 13.21% were experiencing immunological failure (CD4 < 200 cells/mm(3)). The median duration on first-line ART was 36 [IQR: 7-157] months prior to detecting VF, and the rate of switch to second-line ART was 70.75% (75/106). Delay in switching ART after a confirmed VF was 11 [IQR: 7-16] months. After switch to second-line ART, the median time to achieve undetectable VL (<40 copies/ml) was 14 [IQR: 9-21] months. Multivariate analysis revealed that only children with viral rebound (aOR = 0.09; 95% CI = 0.03-0.24) were less likely to be switched. Of note, being orphaned (aOR = 0.35, CI = 0.11-1.11), biological sex (aOR = 1.77, CI = 0.60-5.29) and immune status (aOR = 0.19, CI = 0.03-1.31, 0.09) had no significant effect on switching to second-line ART. Conclusion In this paediatric population experiencing VF after about 3-4 years from ART initiation, the majority are switched to second-line ART after a delay of almost one year. Delayed switch to second-line was driven essentially by viral rebound, underscoring the need for close viral monitoring.
引用
收藏
页码:927 / 935
页数:9
相关论文
共 50 条
  • [1] Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation
    Desmonde, Sophie
    Eboua, Francois T.
    Malateste, Karen
    Dicko, Fatoumata
    Ekouevi, Didier K.
    Ngbeche, Sylvie
    Koueta, Fla
    Sy, Haby Signate
    Renner, Lorna
    Koumakpai, Siriatou A.
    Leroy, Valeriane
    AIDS, 2015, 29 (12) : 1527 - 1536
  • [2] First-line and second-line antiretroviral therapy
    Calmy, A
    Pascual, F
    Ford, N
    LANCET, 2004, 364 (9431): : 329 - 329
  • [3] High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy
    Gupta, Ravindra K.
    Goodall, Ruth L.
    Ranopa, Michael
    Kityo, Cissy
    Munderi, Paula
    Lyagoba, Fred
    Mugarura, Lincoln
    Gilks, Charles F.
    Kaleebu, Pontiano
    Pillay, Deenan
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (07) : 1023 - 1026
  • [4] Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa
    Fox, Matthew P.
    Van Cutsem, Gilles
    Giddy, Janet
    Maskew, Mhairi
    Keiser, Olivia
    Prozesky, Hans
    Wood, Robin
    Hernan, Miguel A.
    Sterne, Jonathan A. C.
    Egger, Matthias
    Boulle, Andrew
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (04) : 428 - 437
  • [5] Association of First-Line and Second-Line Antiretroviral Therapy Adherence
    Ramadhani, Habib O.
    Thielman, John A. Bartlett Nathan M.
    Pence, BrianW.
    Kimani, Stephen M.
    Maro, Venance P.
    Mwako, Mtumwa S.
    Masaki, Lazaro J.
    Mmbando, Calvin E.
    Minja, Mary G.
    Lirhunde, Eileen S.
    Miller, William C.
    OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (02):
  • [6] Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
    Meloni, Seema T.
    Onwuamah, Chika K.
    Agbaji, Oche
    Chaplin, Beth
    Olaleye, David O.
    Audu, Rosemary
    Samuels, Jay
    Ezechi, Oliver
    Imade, Godwin
    Musa, Adesola Z.
    Odaibo, Georgina
    Okpokwu, Jonathan
    Rawizza, Holly
    Mu'azu, Muhammad A.
    Dalhatu, Ibrahim
    Ahmed, Mukhtar
    Okonkwo, Prosper
    Raizes, Elliot
    Ujah, Innocent A. O.
    Yang, Chunfu
    Idigbe, Emmanuel O.
    Kanki, Phyllis J.
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (04):
  • [7] First-line and second-line antiretroviral therapy - Author's reply
    Carr, A
    LANCET, 2004, 364 (9431): : 330 - 330
  • [8] Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study
    Lam, Edward P.
    Moore, Cecilia L.
    Gotuzzo, Eduardo
    Nwizu, Chidi
    Kamarulzaman, Adeeba
    Chetchotisakd, Ploenchan
    van Wyk, Jean
    Teppler, Hedy
    Kumarasamy, Nagalingeswaran
    Molina, Jean-Michel
    Emery, Sean
    Cooper, David A.
    Boyd, Mark A.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (09) : 841 - 850
  • [9] Resistance in Pediatric Patients Experiencing Virologic Failure With First-line and Second-line Antiretroviral Therapy
    Orrell, Catherine
    Levison, Julie
    Ciaranello, Andrea
    Bekker, Linda-Gail
    Kuritzkes, Daniel R.
    Freedberg, Kenneth A.
    Wood, Robin
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (06) : 644 - 647
  • [10] Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial
    Kambugu, Andrew
    Thompson, Jennifer
    Hakim, James
    Tumukunde, Dinah
    van Oosterhout, Joep J.
    Mwebaze, Raymond
    Hoppe, Anne
    Abach, James
    Kwobah, Charles
    Arenas-Pinto, Alejandro
    Walker, Sarah A.
    Paton, Nicholas I.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (05) : 506 - 513